Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine With Antiangiogenic Peptide Vaccine Therapy in Patients With Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~DISEASE CHARACTERISTICS~1. locally advanced or metastatic pancreatic cancer precluding curative surgical resection and recurrent pancreatic cancer~2. measurable disease by CT scan~PATIENT CHARACTERISTICS~1. ECOG performance status 0-2~2. Life expectancy \> 3 months~3. Laboratory values as follows~   * 2000/mm3 \< WBC \< 15000/mm3~  * Platelet count \> 75000/mm3~  * Bilirubin \< 3.0 mg/dl~  * Aspartate transaminase \< 150 IU/L~  * Alanine transaminase \< 150 IU/L~  * Creatinine \< 3.0 mg/dl~4. HLA-A\*2402~5. Able and willing to give valid written informed consent~Exclusion Criteria:~1. Pregnancy(woman of childbearing potential:Refusal or inability to use effective means of contraception)~2. Breastfeeding~3. Active or uncontrolled infection~4. Concurrent treatment with steroids or immunosuppressing agent~5. Prior chemotherapy of gemcitabine~6. Prior chemotherapy,radiation therapy, or immunotherapy within 4 weeks~7. Serious or nonhealing wound, ulcer, or bone fracture~8. Active or uncontrolled other malignancy~9. Ileus~10. Interstitial pneumonia~11. Decision of unsuitableness by principal investigator or physician-in-charge

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Phase I study (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).